{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:33:53Z","timestamp":1770330833845,"version":"3.49.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019655","name":"ICW Healthcare Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.vaccine.2023.12.024","type":"journal-article","created":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T13:24:42Z","timestamp":1702733082000},"page":"162-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A multifaceted approach for identification, validation, and immunogenicity of naturally processed and in silico-predicted highly conserved SARS-CoV-2 peptides"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1446-1188","authenticated-orcid":false,"given":"Tamar","family":"Ratishvili","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huy Quang","family":"Quach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2856-0590","authenticated-orcid":false,"given":"Iana H.","family":"Haralambieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogesh R.","family":"Suryawanshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inna G.","family":"Ovsyannikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6164-4967","authenticated-orcid":false,"given":"Richard B.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Poland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.12.024_b0005","unstructured":"Mathieu E, Ritchie H, Rod\u00e9s-Guirao L, Appel C, Giattino C, Hasell J, et al. \u201cCoronavirus Pandemic (COVID-19)\u201d. Published online at OurWorldInData.org. Retrieved from: https:\/\/ourworldindata.org\/coronavirus. 2020."},{"key":"10.1016\/j.vaccine.2023.12.024_b0010","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1001\/jama.2022.17876","article-title":"Association of primary and booster vaccination and prior infection with SARS-CoV-2 infection and severe COVID-19 outcomes","volume":"328","author":"Lin","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.12.024_b0015","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.12.024_b0020","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41586-022-05053-w","article-title":"Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5","volume":"608","author":"Wang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.12.024_b0025","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMc2119358","article-title":"Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection","volume":"386","author":"Nemet","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.12.024_b0030","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMc2119270","article-title":"Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa","volume":"386","author":"Collie","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.12.024_b0035","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02979-21","article-title":"The impact of evolving SARS-CoV-2 mutations and variants on COVID-19 Vaccines","volume":"13","author":"McLean","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2023.12.024_b0040","article-title":"Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster","author":"Kurhade","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2023.12.024_b0045","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2213907","article-title":"Antibody Response to Omicron BA.4-BA.5 Bivalent Booster","volume":"388","author":"Wang","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.12.024_b0050","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1016\/j.vaccine.2021.06.028","article-title":"The need for broadly protective COVID-19 vaccines: beyond S-only approaches","volume":"39","author":"Poland","year":"2021","journal-title":"Vaccine"},{"issue":"271\u201380","key":"10.1016\/j.vaccine.2023.12.024_b0055","first-page":"e8","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2023.12.024_b0060","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.12.024_b0065","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41467-022-29225-4","article-title":"Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors","volume":"13","author":"Perez-Alos","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.12.024_b0070","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1146\/annurev-immunol-101721-061120","article-title":"T cell responses to SARS-CoV-2","volume":"41","author":"Sette","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2023.12.024_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137155","article-title":"Early and polyantigenic CD4 T cell responses correlate with mild disease in acute COVID-19 donors","volume":"23","author":"Tarke","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2023.12.024_b0080","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2023.12.024_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108728","article-title":"Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients","volume":"34","author":"Tan","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2023.12.024_b0090","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.immuni.2020.10.006","article-title":"Unbiased Screens Show CD8(+) T cells of COVID-19 patients recognize shared epitopes in SARS-CoV-2 that largely reside outside the spike protein","volume":"53","author":"Ferretti","year":"2020","journal-title":"Immunity"},{"issue":"847\u201359","key":"10.1016\/j.vaccine.2023.12.024_b0095","first-page":"e11","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron","volume":"185","author":"Tarke","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2023.12.024_b0100","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41586-022-04460-3","article-title":"T cell responses to SARS-CoV-2 spike cross-recognize Omicron","volume":"603","author":"Keeton","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.12.024_b0105","article-title":"Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients","author":"GeurtsvanKessel","year":"202272202","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2023.12.024_b0110","doi-asserted-by":"crossref","first-page":"e2164219","DOI":"10.1080\/22221751.2022.2164219","article-title":"The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development","volume":"12","author":"Yu","year":"2023","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2023.12.024_b0115","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-022-00884-5","article-title":"Structural biology of SARS-CoV-2: open the door for novel therapies","volume":"7","author":"Yan","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.vaccine.2023.12.024_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2022.152302","article-title":"A review on structural, non-structural, and accessory proteins of SARS-CoV-2: Highlighting drug target sites","volume":"228","author":"Jahirul Islam","year":"2023","journal-title":"Immunobiology"},{"key":"10.1016\/j.vaccine.2023.12.024_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113889","article-title":"The role of SARS-CoV-2 accessory proteins in immune evasion","volume":"156","author":"Zandi","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.vaccine.2023.12.024_b0130","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00451-23","article-title":"SARS-CoV-2 ORF8 accessory protein is a virulence factor","volume":"14","author":"Bello-Perez","year":"2023","journal-title":"mBio."},{"key":"10.1016\/j.vaccine.2023.12.024_b0135","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1128\/JVI.78.1.42-51.2004","article-title":"Identification and characterization of novel, naturally processed measles virus class II HLA-DRB1 peptides","volume":"78","author":"Ovsyannikova","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.12.024_b0140","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.vaccine.2009.09.126","article-title":"Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development","volume":"28","author":"Johnson","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.12.024_b0145","doi-asserted-by":"crossref","first-page":"e0252198","DOI":"10.1371\/journal.pone.0252198","article-title":"Identification of naturally processed Zika virus peptides by mass spectrometry and validation of memory T cell recall responses in Zika convalescent subjects","volume":"16","author":"Crooke","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.12.024_b0150","doi-asserted-by":"crossref","first-page":"15401","DOI":"10.1038\/s41598-022-19679-3","article-title":"Evaluating immunogenicity of pathogen-derived T-cell epitopes to design a peptide-based smallpox vaccine","volume":"12","author":"Quach","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.12.024_b0155","doi-asserted-by":"crossref","first-page":"14179","DOI":"10.1038\/s41598-020-70864-8","article-title":"Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome","volume":"10","author":"Crooke","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.12.024_b0160","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7171\/jbt.18-2902-002","article-title":"The Cellosaurus, a Cell-Line Knowledge Resource","volume":"29","author":"Bairoch","year":"2018","journal-title":"J Biomol Tech"},{"key":"10.1016\/j.vaccine.2023.12.024_b0165","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2666-5247(20)30004-5","article-title":"Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study","volume":"1","author":"Chu","year":"2020","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2023.12.024_b0170","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41586-020-2332-7","article-title":"Proteomics of SARS-CoV-2-infected host cells reveals therapy targets","volume":"583","author":"Bojkova","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.12.024_b0175","doi-asserted-by":"crossref","DOI":"10.3390\/v14071369","article-title":"A newly engineered A549 cell line expressing ACE2 and TMPRSS2 is highly permissive to SARS-CoV-2, including the Delta and Omicron variants","volume":"14","author":"Chang","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2023.12.024_b0180","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fmicb.2011.00067","article-title":"A novel in vitro human macrophage model to study the persistence of mycobacterium tuberculosis using Vitamin D(3) and retinoic acid activated THP-1 macrophages","volume":"2","author":"Estrella","year":"2011","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2023.12.024_b0185","doi-asserted-by":"crossref","first-page":"D480","DOI":"10.1093\/nar\/gkaa1100","article-title":"UniProt: the universal protein knowledgebase in 2021","volume":"49","author":"UniProt","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2023.12.024_b0190","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2023.12.024_b0195","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1021\/acs.jproteome.9b00874","article-title":"Improved prediction of MHC II antigen presentation through integration and motif deconvolution of mass spectrometry MHC eluted ligand data","volume":"19","author":"Reynisson","year":"2020","journal-title":"J Proteome Res"},{"key":"10.1016\/j.vaccine.2023.12.024_b0200","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13073-016-0288-x","article-title":"NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets","volume":"8","author":"Nielsen","year":"2016","journal-title":"Genome Med"},{"key":"10.1016\/j.vaccine.2023.12.024_b0205","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","author":"Peng","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2023.12.024_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108454","article-title":"The human leukocyte antigen class II immunopeptidome of the SARS-CoV-2 spike glycoprotein","volume":"33","author":"Knierman","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2023.12.024_b0215","doi-asserted-by":"crossref","first-page":"D339","DOI":"10.1093\/nar\/gky1006","article-title":"The Immune Epitope Database (IEDB): 2018 update","volume":"47","author":"Vita","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2023.12.024_b0220","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2105-7-153","article-title":"Predicting population coverage of T-cell epitope-based diagnostics and vaccines","volume":"7","author":"Bui","year":"2006","journal-title":"BMC Bioinf"},{"key":"10.1016\/j.vaccine.2023.12.024_b0225","first-page":"D783","article-title":"Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools","volume":"48","author":"Gonzalez-Galarza","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2023.12.024_b0230","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.46234\/ccdcw2021.255","article-title":"GISAID's Role in Pandemic Response","volume":"3","author":"Khare","year":"2021","journal-title":"China CDC Wkly"},{"key":"10.1016\/j.vaccine.2023.12.024_b0235","doi-asserted-by":"crossref","first-page":"D67","DOI":"10.1093\/nar\/gkv1276","article-title":"GenBank","volume":"44","author":"Clark","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2023.12.024_b0240","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.3390\/v4113209","article-title":"Virus pathogen database and analysis resource (ViPR): a comprehensive bioinformatics database and analysis resource for the coronavirus research community","volume":"4","author":"Pickett","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2023.12.024_b0245","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/msb.2011.75","article-title":"Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega","volume":"7","author":"Sievers","year":"2011","journal-title":"Mol Syst Biol"},{"key":"10.1016\/j.vaccine.2023.12.024_b0250","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/1471-2105-8-361","article-title":"Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines","volume":"8","author":"Bui","year":"2007","journal-title":"BMC Bioinf"},{"key":"10.1016\/j.vaccine.2023.12.024_b0255","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1038\/s41467-022-32262-8","article-title":"SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization","volume":"13","author":"Mannar","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.12.024_b0260","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111815118","article-title":"Mass spectrometric identification of immunogenic SARS-CoV-2 epitopes and cognate TCRs","volume":"118","author":"Pan","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2023.12.024_b0265","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1080\/22221751.2020.1827985","article-title":"Robust and persistent SARS-CoV-2 infection in the human intestinal brush border expressing cells","volume":"9","author":"Lee","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.vaccine.2023.12.024_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109305","article-title":"Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics","volume":"35","author":"Nagler","year":"2021","journal-title":"Cell Rep"},{"issue":"3962\u201380","key":"10.1016\/j.vaccine.2023.12.024_b0275","first-page":"e17","article-title":"Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs","volume":"184","author":"Weingarten-Gabbay","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2023.12.024_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107863","article-title":"Critical role of type III interferon in controlling SARS-CoV-2 infection in human intestinal epithelial cells","volume":"32","author":"Stanifer","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2023.12.024_b0285","doi-asserted-by":"crossref","DOI":"10.3390\/v14040704","article-title":"Effect of short time of SARS-CoV-2 infection in Caco-2 cells","volume":"14","author":"Zupin","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2023.12.024_b0290","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1074\/mcp.M114.042812","article-title":"Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation","volume":"14","author":"Bassani-Sternberg","year":"2015","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.vaccine.2023.12.024_b0295","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","article-title":"SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition","volume":"22","author":"Nelde","year":"2021","journal-title":"Nat Immunol"},{"issue":"1489\u2013501","key":"10.1016\/j.vaccine.2023.12.024_b0300","first-page":"e15","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2023.12.024_b0305","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.12.024_b0310","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.4049\/jimmunol.2001438","article-title":"Genome-Wide B Cell, CD4(+), and CD8(+) T cell epitopes that are highly conserved between human and animal coronaviruses, identified from SARS-CoV-2 as targets for preemptive pan-coronavirus vaccines","volume":"206","author":"Prakash","year":"2021","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2023.12.024_b0315","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41541-021-00331-6","article-title":"Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation","volume":"6","author":"Meyers","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2023.12.024_b0320","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.167306","article-title":"Single-epitope T cell-based vaccine protects against SARS-CoV-2 infection in a preclinical animal model","volume":"8","author":"Tada","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.vaccine.2023.12.024_b0325","doi-asserted-by":"crossref","first-page":"3966","DOI":"10.1038\/s41467-022-31721-6","article-title":"A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection","volume":"13","author":"Pardieck","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.12.024_b0330","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41586-021-04232-5","article-title":"A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity","volume":"601","author":"Heitmann","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.12.024_b0335","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/vaccines2030515","article-title":"Peptide vaccine: progress and challenges","volume":"2","author":"Li","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.12.024_b0340","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg6461","article-title":"SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8(+) T cell responses","volume":"6","author":"Agerer","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2023.12.024_b0345","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl5394","article-title":"High-resolution profiling of MHC II peptide presentation capacity reveals SARS-CoV-2 CD4 T cell targets and mechanisms of immune escape","volume":"8","author":"Obermair","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.vaccine.2023.12.024_b0350","article-title":"Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals","volume":"2","author":"Tarke","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.vaccine.2023.12.024_b0355","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.chom.2021.05.010","article-title":"SARS-CoV-2 human T cell epitopes: adaptive immune response against COVID-19","volume":"29","author":"Grifoni","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2023.12.024_b0360","doi-asserted-by":"crossref","first-page":"376","DOI":"10.4049\/jimmunol.2100421","article-title":"Cutting edge: nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity","volume":"207","author":"Matchett","year":"2021","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2023.12.024_b0365","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.158126","article-title":"T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components","volume":"7","author":"Jing","year":"2022","journal-title":"JCI Insight"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23014688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23014688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T14:58:52Z","timestamp":1715180332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23014688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0264410X23014688"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.12.024","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multifaceted approach for identification, validation, and immunogenicity of naturally processed and in silico-predicted highly conserved SARS-CoV-2 peptides","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}